{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Control+Subjects&page=23",
    "query": {
      "condition": "Control Subjects",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 5448,
    "total_pages": 545,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Control+Subjects&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Control+Subjects&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T21:28:32.324Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05466890",
      "title": "Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ulcerative Colitis",
        "Ulcerative Colitis Acute",
        "Ulcerative",
        "Ulcerative Colitis Flare"
      ],
      "interventions": [
        {
          "name": "PL8177 Placebo",
          "type": "DRUG"
        },
        {
          "name": "PL8177",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Palatin Technologies, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 16,
      "start_date": "2022-09-15",
      "completion_date": "2025-03-31",
      "has_results": false,
      "last_update_posted_date": "2025-03-05",
      "last_synced_at": "2026-10-20T21:28:32.324Z",
      "location_count": 14,
      "location_summary": "Tucson, Arizona • Lancaster, California • Tarzana, California + 11 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Tarzana",
          "state": "California"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05466890"
    },
    {
      "nct_id": "NCT03548220",
      "title": "A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pyruvate Kinase Deficiency",
        "Anemia, Hemolytic"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "AG-348",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agios Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2018-08-09",
      "completion_date": "2020-10-09",
      "has_results": true,
      "last_update_posted_date": "2022-05-24",
      "last_synced_at": "2026-10-20T21:28:32.324Z",
      "location_count": 12,
      "location_summary": "Little Rock, Arkansas • Atlanta, Georgia • Indianapolis, Indiana + 8 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03548220"
    },
    {
      "nct_id": "NCT05198323",
      "title": "A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "LT3001 Drug Product",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lumosa Therapeutics Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 66,
      "start_date": "2022-08-11",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-10-20T21:28:32.324Z",
      "location_count": 1,
      "location_summary": "Chattanooga, Tennessee",
      "locations": [
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05198323"
    },
    {
      "nct_id": "NCT03955146",
      "title": "Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "Pamrevlumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kyntra Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 393,
      "start_date": "2019-06-18",
      "completion_date": "2023-08-28",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-20T21:28:32.324Z",
      "location_count": 60,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03955146"
    },
    {
      "nct_id": "NCT03097978",
      "title": "Comparison of Pattern Recognition Control and Direct Control in TMR",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Amputation",
        "Amputation; Traumatic, Arm, Upper"
      ],
      "interventions": [
        {
          "name": "Commercial system",
          "type": "DEVICE"
        },
        {
          "name": "RIC arm system",
          "type": "DEVICE"
        },
        {
          "name": "Direct Control",
          "type": "OTHER"
        },
        {
          "name": "Pattern Recognition",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Shirley Ryan AbilityLab",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "18 Years to 95 Years"
      },
      "enrollment_count": 11,
      "start_date": "2013-06",
      "completion_date": "2017-09-29",
      "has_results": false,
      "last_update_posted_date": "2018-02-23",
      "last_synced_at": "2026-10-20T21:28:32.324Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03097978"
    },
    {
      "nct_id": "NCT05737485",
      "title": "Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Primary Ciliary Dyskinesia"
      ],
      "interventions": [
        {
          "name": "RCT1100",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ReCode Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 9,
      "start_date": "2023-02-18",
      "completion_date": "2025-01-13",
      "has_results": false,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-10-20T21:28:32.324Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05737485"
    },
    {
      "nct_id": "NCT01021891",
      "title": "A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "Technosphere®/Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 39,
      "start_date": "2006-07",
      "completion_date": "2008-11",
      "has_results": false,
      "last_update_posted_date": "2013-12-17",
      "last_synced_at": "2026-10-20T21:28:32.324Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01021891"
    },
    {
      "nct_id": "NCT03827018",
      "title": "KPL-301 for Subjects With Giant Cell Arteritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Giant Cell Arteritis"
      ],
      "interventions": [
        {
          "name": "mavrilimumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "placebo",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Kiniksa Pharmaceuticals, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 70,
      "start_date": "2018-09-20",
      "completion_date": "2020-11-25",
      "has_results": true,
      "last_update_posted_date": "2023-10-23",
      "last_synced_at": "2026-10-20T21:28:32.324Z",
      "location_count": 8,
      "location_summary": "Sarasota, Florida • Tampa, Florida • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Lansing",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03827018"
    },
    {
      "nct_id": "NCT02188160",
      "title": "Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Syndromes",
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "KPI-121",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kala Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2014-06",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2021-01-06",
      "last_synced_at": "2026-10-20T21:28:32.324Z",
      "location_count": 11,
      "location_summary": "Artesia, California • Mission Hills, California • Rancho Cordova, California + 8 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Rancho Cordova",
          "state": "California"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02188160"
    },
    {
      "nct_id": "NCT04854096",
      "title": "Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Myelofibrosis",
        "Post-essential Thrombocythemia Myelofibrosis",
        "Post-polycythemia Vera Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "NS-018",
          "type": "DRUG"
        },
        {
          "name": "Best Available Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NS Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2023-01-31",
      "completion_date": "2024-05-16",
      "has_results": true,
      "last_update_posted_date": "2025-05-23",
      "last_synced_at": "2026-10-20T21:28:32.324Z",
      "location_count": 3,
      "location_summary": "Worcester, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04854096"
    }
  ]
}